Shares in Volition closed at US$5.55 a share in New York.
Cancer diagnostics group Ltd (NYSEMKT:VNRX) said its previously-announced share offer has been priced at US$5 a share.
The life sciences company is set to raise around US$11.25mln through the underwritten public offer.
Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and for other general corporate purposes.
Shares in Volition currently trade at around US$5.55 a share in New York.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE